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In 2003 we highlighted aspects of phenotypic overlap be-
tween the rare Mendelian encephalopathy Aicardi-Goutières 
syndrome (AGS), the complex autoimmune disease systemic 
lupus erythematosus (SLE), and certain congenital viral in-
fections, including transplacentally acquired human immu-
nodeficiency virus (HIV-1), and postulated that this overlap 
might result from the common pathological feature of an up- 
regulation of interferon α activity (Crow et al., 2003). The 
subsequent partial dissection of the genetic basis of AGS 
(Crow et al., 2006a,b; Rice et al., 2009), the molecular defi-
nition of a monogenic form of SLE associated with up- 
regulated type I interferon (Briggs et al., 2011; Lausch et al., 
2011), and the developing understanding of a primary link 
between nucleic acid metabolism and interferon induction 
led to the proposition, in 2011, of the grouping of Mendelian 
disorders associated with an up-regulation of type I interferon 
signaling as a novel set of human inborn errors of immunity, 
in which such constitutive up-regulation is central to patho-
genesis (Crow, 2011). In 2015, a framework was proposed for 
the consideration of the pathogenesis of this group of diseases 
(Crow, 2015; Crow and Manel, 2015), which can be viewed 
as analogous to previously described single-gene defects in 
immune signaling pathways leading to primary immunodefi-
ciency (Casanova et al., 2005) and monogenic autoinflamma-
tion (Kastner et al., 2010).
At the outset, it is important to state that, as strictly 
defined, the central tenet of the type I interferonopathy con-
cept remains unproven; i.e., definitive evidence that pathology 
is determined by an up-regulation of type I interferon signal-
ing is lacking. Indeed, it will not be until we have therapeutic 
agents that specifically target type I interferon signaling, and 
use them in putative type I interferonopathy patients, that 
the contribution of type I interferon to clinical phenotype 
will become clear. Simply put, at this time, it is still possible 
that the finding of up-regulated type I interferon signaling 
in certain phenotypes represents an association rather than a 
pathologically causal relationship. That being said, as we argue 
below, the observation of phenotypic overlap, the elucidation 
of shared pathomechanisms through human genetics, in vitro 
and in vivo experimentation, and the first results of early 
treatment trials all give support to the scientific validity of the 
type I interferonopathy grouping.
Because this is a field in its infancy, it is necessary to 
avoid being overly didactic. Thus, except in a few cases, most 
notably perhaps disease related to mutations in TREX1 and 
RNA SEH2B, it is important to acknowledge that the true 
clinical spectrum and frequency of features associated with 
particular genotypes is likely not known. This point is well 
illustrated by the expansion of the phenotype associated 
with mutations in TMEM173 in a period of a little over two 
years, now spanning early-onset systemic inflammation with 
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mutilating skin lesions and lethal pulmonary inflammation 
(Jeremiah et al., 2014; Liu et al., 2014), through to “idio-
pathic” lung fibrosis (Clarke et al., 2016; Picard et al., 2016) 
and isolated chilblain lupus inherited stably across several 
generations (König et al., 2016). Similar uncertainty exists in 
regard to questions central to disease pathogenesis, e.g., the 
exact source and nature of the endogenous ligands considered 
to induce a type I interferon response in certain of the type 
I interferonopathies. As such, the aim here is to draw out 
general themes relating to phenotype and pathology, fully 
expecting that our understanding of detail will change over 
the short to medium term.
Which diseases should be considered  
as type I interferonopathies?
Given that the acid test of response to anti-interferon ther-
apy is not yet available, here we base our inclusion of distinct 
monogenic disorders as type I interferonopathies on evidence 
indicating a persistent up-regulation of type I interferon sig-
naling, assessed by measuring the expression of interferon- 
stimulated genes (ISGs) and/or in vivo (animal)/ex vivo/in vitro 
experimental evidence. This group thus comprises 18 genotypes in 
which we consider that the link to enhanced interferon signaling 
is established (Table 1 and Fig. 1). The somewhat imprecise nature 
of these criteria means that we do not include, for example, gain-
of-function mutations in STAT1, although it may be that future 
studies will demonstrate a functional relationship of ISG produc-
tion to phenotype. For similar reasons, we exclude discussion of 
DNA SE1L3, chronic granulomatous disease, prolidase de-
ficiency, and some early components of the complement 
cascade, all of which are associated with an increased risk of SLE, 
so that one might predict an up-regulation of type I interferon 
signaling but where the point rests unproven. Other diseases that 
may also come to be considered in this grouping, but where 
we feel that the evidence currently remains uncertain, are those 
caused by mutations in CECR1 (Belot et al., 2014; Uettwiller 
et al., 2016), TRNT1 (Frans et al., 2016), and RNA SET2 
(Tonduti et al., 2016).
It is of course the case that dysfunction of certain proteins 
can have more than one biological consequence. For example, 
in the context of the putative type I interferonopathies, ADAR1 
has both an interferon-related and a distinct developmental 
(MDA5/MAVS independent) function (Pestal et al., 2015). Of 
possible note also, Rnaseh2b knockout confers embryonic 
lethality in the mouse (Hiller et al., 2012; Reijns et al., 2012), in 
the absence of the induction of an interferon response, which 
is seen in the corresponding hypomorphic model (Mackenzie 
et al., 2016; Pokatayev et al., 2016). Whether or not this differ-
ence reflects distinct biological roles of the RNase H2 complex 
or the timing/degree of a shared disturbance of ribonucleo-
tide excision repair remains unknown. The situation appears 
clearer with respect to mutations in SKIV2L causing tricho- 
hepato-enteric syndrome (THES). Here, there is a markedly 
elevated ISG expression and a proven link to interferon signal-
ing via a disturbance of the unfolded protein response (Eckard 
et al., 2014). However, the same disease phenotype can be caused 
by mutations in TTC37, where no such interferon signature 
is present, and where, in contrast to SKIV2L, in vitro assays do 
not suggest a role in interferon signaling. These data lead to the 
conclusion that most of the features of THES are the consequence 
Table 1. Genotypes considered as type I interferonopathies in this manuscript, with protein function, link to interferon signaling, proposed 
molecular mechanism, and currently recognized associated clinical phenotypes
Gene Protein function Sensing/activation pathway related to 
type I interferon signaling
Mutation effect Major patient 
phenotypes
TREX1 Deoxyribonuclease Cytosolic DNA LOF (recessive or dominant-negative) AGS, FCL, SLE
SAM HD1 Control of dNTP pool (±nuclease) Cytosolic DNA (±cytosolic RNA) LOF (recessive) AGS, FCL, CVD
TMEM173 Transduction of cytosolic type I interferon 
signal
Cytosolic DNA (±cytosolic RNA) GOF (dominant) SAVI, FCL 
RNA SEH2A Ribonuclease Cytosolic RNA :DNA hybrids LOF (recessive) AGS
RNA SEH2B Ribonuclease Cytosolic RNA :DNA hybrids LOF (recessive) AGS, SP
RNA SEH2C Ribonuclease Cytosolic RNA :DNA hybrids LOF (recessive) AGS
POLA1 Polymerase Cytosolic RNA :DNA hybrids X-linked recessive XLP DR
ADAR1 RNA editing Cytosolic RNA LOF (recessive or dominant-negative) AGS, DSH, BSN, SP
IFIH1 dsRNA sensor Cytosolic RNA GOF (dominant) AGS, SP, SMS
RIG-I dsRNA sensor Cytosolic RNA GOF (dominant) Atypical SMS
SKIV2L RNA helicase Cytosolic RNA LOF (recessive) THES
UPS18 Inhibition of ISG transcription IFN AR1 signaling LOF (recessive) pseudo-TOR CH
ISG15 Inhibition of ISG transcription IFN AR1 signaling LOF (recessive) MSMD, ICC 
PSMB8 Proteasome Unknown LOF (recessive) PRA AS
PSMB4 Proteasome Unknown LOF (recessive) PRA AS
PSMA3 Proteasome Unknown LOF (recessive) PRA AS
ACP5 Phosphatase activity related to 
osteopontin
Unknown LOF (recessive) SPE NCD, SLE, cytopenias 
C1q Alternative complement pathway activity Unknown LOF (recessive) SLE
BSN, bilateral striatal necrosis; CVD, cerebrovascular disease; DSH, dyschromatosis symmetrica hereditaria; FCL, familial chilblain lupus; GOF, gain-of-function; ICC, intracranial calcification; 
LOF, loss-of-function; MSMD, Mendelian susceptibility to mycobacterial disease; PRA AS, proteasome-associated autoinflammatory syndrome; SAVI, STI NG-associated vasculopathy with 
onset in infancy; SMS, Singleton-Merten syndrome; SP, spastic paraparesis; SPE NCD, spondyloenchondrodysplasia; XLP DR, X-linked reticulate pigmentary disorder.
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of a loss of cytosolic RNA exosome function in RNA turnover, 
rather than an aberrant interferon response that is apparently 
specific to SKIV2L deficiency.
It is interesting to view the aforementioned observations 
in regards to the potential efficacy of future anti-interferon 
therapy. Thus, the involvement/dysfunction of noninterfer-
on-related disease pathways in a phenotype would variably 
limit the efficacy of such treatment. On this basis then, one 
can conceptualize the existence of more “pure” interferono- 
pathies, where anti-interferon therapy would be expected 
to have the greatest benefit, and “mixed” phenotypes, where 
such therapies would be of more limited or, indeed, no utility.
Is it appropriate to use the term type I 
interferonopathies (I)?
In 1957 Isaacs and Lindenmann described a soluble factor 
that protects cells from viral infection, which agent, in con-
sideration of its antiviral interfering properties, they termed 
interferon (Isaacs and Lindenmann, 1957; Isaacs et al., 1957). 
We now know that multiple species of type I interferon exist, 
with this heterogeneity arising from the presence of 13 func-
tional α genes and single genes for interferon β, ε, κ, and ω. 
Despite almost 60 years of active research, an understanding 
of the role of these different interferon species has been ham-
pered by the inability to directly measure type I interferon 
Figure 1. Type I interferon signaling and type I interferonopathies as currently assigned. Diseases considered as monogenic interferonopathies 
are represented by blue boxes. This schema alludes to at least seven possible cellular mechanisms resulting in sustained activation of interferon signaling 
caused by the following: (1) loss-of-function mutations leading to increased cytosolic DNA (TREX1 [Stetson et al., 2008] and SAM HD1 [Behrendt et al., 
2013; Rehwinkel et al., 2013]) or RNA/DNA hybrid (RNA SEH2A, RNA SEH2B and RNA SEH2C, POLA1) sensing (Hiller et al., 2012; Mackenzie et al., 2016; 
Starokadomskyy et al., 2016); (2) loss-of-function mutations leading to a defect in RNA editing and abnormal sensing of self–nucleic acid RNA species 
in the cytosol (ADAR1 [Liddicoat et al., 2015; Pestal et al., 2015]); (3) gain-of-function mutations leading to constitutive activation of cytosolic interferon 
signaling pathways/increased sensitivity to cytosolic nucleic acid ligands (MDA5 [Rice et al., 2014], RIG-I [Jang et al., 2015], and STI NG [Liu et al., 2014]); 
(4) loss-of-function mutations leading to aberrant RNA signaling via MAVS caused by a disturbance of the unfolded protein response (SKIV2L [Eckard et 
al., 2014]); (5) loss-of-function mutations in molecules responsible for limiting interferon receptor (IFN AR1/2) signaling leading to uncontrolled ISG pro-
duction (USP18 [Meuwissen et al., 2016] and ISG15 [Zhang et al., 2015]); (6) proteasomal dysfunction leading to increased interferon signaling through an 
unknown mechanism (PSMA3, PSMB4, and PSMB8 [Brehm et al., 2015]; we do not include the so-far single-published mutations in PSMB9 and POMP); and 
(7) loss-of-function mutations in TRAP/ACP5 (Briggs et al., 2011; Lausch et al., 2011) and C1q (Lood et al., 2009; Santer et al., 2010) where we consider the 
mechanisms leading to type I interferon signaling are yet to be fully clarified (we do not include mutations in other molecules of the complement pathway 
as a clear demonstration of enhanced interferon signaling has not been established).
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protein in biological samples using available ELI SAs. Corre-
spondingly, type I interferon mRNA is usually unrecordable 
in peripheral blood from healthy individuals, even after vacci-
nation (Sobolev et al., 2016), or in patients with putative type 
I interferonopathies. Such low levels of circulating interferons 
likely reflect the very high biological potency of these cyto-
kines, with most cell types expressing a type I interferon re-
ceptor. As a practical work-around of this problem, researchers 
have made extensive use of the measurement of the mRNA 
of genes that are induced by interferon (ISGs), thus effectively 
capturing an amplified signal consequent upon the interferon 
stimulus (Baechler et al., 2003; Bennett et al., 2003). Indeed, 
we have shown that the measurement of six ISGs represents a 
powerful screening tool for the identification of several of the 
putative type I interferonopathies (Rice et al., 2013).
The repertoire of ISGs produced in response to type 
I, II, or III interferons show considerable overlap, begging 
the legitimate question as to whether or not it is type I 
interferons that are relevant—solely, partially, or not at all—
to the up-regulation of ISGs seen in the diseases discussed 
here. At least in the context of AGS, data have been pub-
lished to indicate that interferon activity in patient material, 
as measured using an antiviral cytopathic protection assay, can 
be neutralized by antiserum against interferon α but not β 
(Lebon et al., 2002; Rice et al., 2013). Furthermore, levels of 
interferon γ were below the detectable range of a sensitive 
ELI SA, and thus possibly inconsistent with the degree of inter-
feron activity recorded in certain of these samples. Although 
these data are important, the field awaits the availability of 
high-sensitivity protein assays allowing the quantification of 
discrete interferons, at least in circulation. Such a tool could 
be usefully combined with measures of ISG production and/
or interferon activity, thus capturing the relationship between 
the inducing (protein) signal and the response (ISGs/antiviral 
activity) to that signal and thereby enabling an exploration of 
interferon signaling dynamics. As we have previously noted, 
the absence of a reliable, high-throughput measure of type I 
interferon in routine medical practice goes some way to ex-
plaining why the concept of the type I interferonopathies as a 
discrete pathological grouping has only recently been mooted.
Is it appropriate to use the term type I 
interferonopathies (II)?
Returning to an earlier point, the question arises as to whether 
the enhanced interferon signaling identified in the proposed 
type I interferonopathies represents a true pathological factor 
or simply a disease biomarker. The answer to this question 
is of fundamental importance because the former possibility 
implies the potential utility of therapeutic approaches target-
ing interferon up- and downstream signaling.
Considering clinically derived observations, the fact 
that, in its classical form (Aicardi and Goutières, 1984), AGS 
is such a remarkable Mendelian mimic of certain congen-
ital infections provides circumstantial support to the up- 
regulation of interferon signaling, recorded in both situa-
tions, representing a common pathogenic link. Second, nu-
merous reports describe the occurrence, after treatment with 
interferon, of features such as digital vasculitis (Al-Zahrani 
et al., 2003), SLE (Rönnblom et al., 1990), and glaucoma 
(Kwon et al., 2001), which are also seen in the putative type I 
interferonopathies. As a final point, and as discussed in more 
detail below, the recognition of a shared set of clinical signs, 
most particularly intracranial calcification and skin inflamma-
tion, across several of these genotypes is further evidence in 
favor of pathogenic overlap.
Experimental evidence also supports a primary role for 
interferon in the diseases discussed here. Likely indicative of 
intrathecal synthesis, levels of interferon activity in the cere-
brospinal fluid of AGS patients are consistently higher than 
in matched serum samples (Crow et al., 2015). Undoubtedly, 
interferon is a neurotoxin, and experiments undertaken in 
mice demonstrate that overexpression of interferon in the 
central nervous system (CNS) results in neuropathology 
reminiscent of that seen in certain type I interferonopathies 
(Akwa et al., 1998; Campbell et al., 1999; Kavanagh et al., 
2016). Relevant crosses in other mouse models, in particu-
lar double knockouts involving the type I interferon recep-
tor, provide unequivocal evidence of the importance of type 
I interferon signaling in these settings (Stetson et al., 2008; 
Goldmann et al., 2015). Furthermore, given that cytosolic 
nucleic acid recognition represents a principal trigger for the 
induction of type I interferon, it is of note that 11 of the 18 
diseases discussed here involve mutations in genes known to 
play a role in nucleic acid metabolism/signaling. We high-
light particularly that gain-of-function mutations in MDA5 
(IFIH1), RIG-I (DDX58), and STI NG (TMEM173), essen-
tial components of cytosolic nucleic acid signaling to a type 
I interferon response, and biallelic loss-of-function mutations 
in USP18 or ISG15, both involved in the negative regulation 
of ISG expression, are all associated with currently recognized 
type I interferonopathy phenotypes.
Phenotypic overlap and differences, variable 
expression, and nonpenetrance
As touched on above, there is a striking overlap of clinical 
features, particularly the involvement of the CNS and the 
skin, across several of the disorders classified here as type 
interferonopathies (Fig.  2). Indeed, we would highlight the 
value of searching for the presence of intracranial calcifica-
tion, most easily appreciated on computed tomography, even 
in the absence of overt neurological signs, and the presence 
of vasculitic/chilblain-like skin lesions as highly useful clini-
cal markers of this disease grouping. At the same time, major 
phenotypic differences exist between certain of these geno-
types. Thus, the severe lung disease that frequently accompa-
nies mutations in TMEM173 has not been reported in the 
context of other putative type I interferonopathies, whereas 
the essentially distinct complex diseases SLE, systemic scle-
rosis, and dermatomyositis all correlate with the presence of 
a type I interferon signature. Such observations apparently 
2531JEM Vol. 213, No. 12
challenge the suggestion of the primacy of interferon as a 
shared pathogenic molecule. While acknowledging this point, 
we have already highlighted that dysfunction of certain pro-
teins can have more than one biological consequence, which 
might explain different phenotypic characteristics across gen-
otypes. Furthermore, distinct expression patterns of relevant 
disease-associated proteins, their protein partners, interfer-
on-inducing signaling components, and proteins involved in 
alternative (“redundant”) signaling pathways according to the 
gene/protein mutated might also be relevant. Finally, we draw 
attention to the possible importance of the timing of a puta-
tive interferon-related insult. Perhaps instructive here, similar 
to AGS, congenital HIV-1 infection is characterized by in-
tracranial calcification, white matter abnormalities, cerebral 
atrophy, and high levels of interferon α (Kauffman et al., 1992; 
Krivine et al., 1992; DeCarli et al., 1993), whereas these ra-
diological signs are not seen with postnatally acquired HIV-1 
infections, suggesting that the developing brain is specifically 
susceptible to intrauterine viral exposure/the host interferon 
response (Tardieu et al., 2000).
It is also pertinent to acknowledge the variable 
expression, and even nonpenetrance, seen in certain type I 
interferonopathies, particularly relating to the recurrent dom-
inant-negative mutations in ADAR1 (Gly1007Arg; Rice et 
al., 2012; Livingston et al., 2014) and TREX1 (p.Asp18Asn; 
Abe et al., 2013) and dominant gain-of-function mutations 
in IFIH1 (Rice et al., 2014) and TMEM173 (Jeremiah et al., 
2014). To explain these observations, we need to invoke dif-
ferential exposure to environmental triggers such as infec-
tion or the effect of genetic modifiers. Indeed, considering 
a putative role of physical stressors, note should be made of 
the cold dependency of the skin lesions seen in the type I 
interferonopathies and of a striking temporal relationship be-
tween the onset of ADAR1-related bilateral striatal necrosis 
Figure 2. Specific and overlapping features of monogenic type I interferonopathies. In the broadest sense, CNS and skin disease are the most 
common features of the type I interferonopathies. Discrete neurological phenotypes associated with mutations in AGS-associated genes include “nonsyn-
dromic” spastic paraparesis (RNA SEH2B, ADAR1, and IFIH1 [Crow et al., 2014]) and bilateral striatal necrosis (ADAR1 [Livingston et al., 2014]). Glaucoma is 
a common feature of AGS (Crow et al., 2015) and is also seen in the Singleton-Merton syndrome phenotype associated with gain-of-function mutations 
in IFIH1 (Bursztejn et al., 2015; Rutsch et al., 2015) and DDX58 (RIG-I [Jang et al., 2015]). SLE (lupus) is most frequently associated with mutations in ACP5 
(An et al., 2016; Briggs et al., 2016) and C1q (Lood et al., 2009; Santer et al., 2010). Malignancy has only been reported in the context of SAM HD1 (Clifford 
et al., 2014; Merati et al., 2015). Lung inflammation is so far restricted to patients with mutations in TMEM173 (STI NG; Liu et al., 2014; Clarke et al., 2016; 
Picard et al., 2016). The phenotypes associated with mutations in POLA1 and SKIV2L appear distinct.
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and preceding infection (Livingston et al., 2014). Whether 
vaccination represents a disease trigger is an important, and 
currently unanswered, question. Meanwhile, the possibility of 
a “cumulative” genetic burden contributing to cellular pa-
thology is notable in light of recently published data on the 
group of type I interferonopathies caused by loss-of-function 
mutations in proteasome subunits (Brehm et al., 2015).
As an allied but distinct point, the identification of 
dominant gain-of-function mutations in IFIH1 has high-
lighted the possibility of clinical nonpenetrance into old age 
in the presence of life-long, marked overexpression of ISGs 
(Rice et al., 2014). This situation is reminiscent of a mouse 
model where transgenic expression of a picornavirus RNA- 
dependent RNA polymerase (RdRP) leads to a dramatic up- 
regulation of ISG stimulation and profound viral resistance 
via an MDA5/MAVS-dependent pathway, but where the 
mice are entirely healthy (Painter et al., 2015). The con-
trast with mouse models also showing type I interferon up- 
regulation, but demonstrating a clear link between interferon 
expression and phenotype, might relate to the involvement 
of other inflammatory cytokines in the latter cases. A fur-
ther possibility is that the constitutively augmented RdRP- 
induced antiviral network is balanced by up-regulation of 
type I interferon negative regulators such as Usp18, and which 
effect might be tissue specific. Interestingly, polymorphisms 
across TMEM173 (Yi et al., 2013) and IFIH1 (Shigemoto et 
al., 2009), some of which occur at relatively high population 
frequencies, can be associated with marked differential inter-
feron induction in vitro. It may be that such genetic varia-
tion reflects an evolutionary balance between the response 
to infection and the risk of inflammatory disease (Sharma et 
al., 2015). The observation of heritable high interferon pro-
duction in certain families demonstrating an increased risk of 
SLE possibly represents a further piece of evidence in favor of 
this hypothesis (Niewold et al., 2007).
Autoinflammation or autoimmunity?
At least in regard to AGS, different authors variably refer to 
the associated pathology as either autoimmune or autoin-
flammatory in basis, with the use of the latter term being 
particularly favored where the emphasis is being placed on 
the link to SLE. A suggested definition of autoinflammation 
relates to disorders characterized by abnormally increased 
inflammation, mediated predominantly by cells and mole-
cules of the innate immune system, with a significant host 
predisposition (Kastner et al., 2010). Thus, according to the 
schema outlined above, we propose that, as a group, the type 
I interferonopathies can reasonably be considered as autoin-
flammatory in origin, with “spill-over” into autoimmunity in 
some cases. Having made this point, we would add that rather 
than being overly concerned by questions of classification, 
the cornerstone of the type I interferonopathy concept, as 
envisaged here, relates to a primary role of type I interferon in 
disease pathogenesis, irrespective of the relative involvement 
of innate/adaptive immune components.
There is a clear association of certain type I interfer-
onopathies with autoimmunity, and SLE in particular, as 
indicated by the co-occurrence of such rare phenotypes 
(e.g., Dale et al., 2000; De Laet et al., 2005; Hacohen et al., 
2015; Van Eyck et al., 2015). Furthermore, a broad spectrum 
of autoantibodies has been observed in patients with AGS 
(Cuadrado et al., 2015a; Zhang et al., 2015; Cattalini et al., 
2016), albeit distinct from other autoimmune diseases. At the 
same time, it is striking that monogenic interferon-related 
inflammation, as so-far defined, is most frequently unaccom-
panied by frank autoimmunity (Crow et al., 2015), so that it 
is difficult to know if these autoantibodies are pathologically 
relevant or represent an epiphenomenon consequent upon a 
more general immune dysregulation. The (inconsistent) link 
to overt autoimmunity in certain type I interferonopathies 
might reflect variable engagement of the adaptive immune 
system secondary to an initial, interferon-associated, innate 
immune disturbance. Having said this, in contrast to AGS 
and STI NG-related disease for example, there is a remark-
ably high risk of autoimmune cytopenias and early-onset 
SLE in the context of mutations in ACP5 (Briggs et al., 2011, 
2016; Lausch et al., 2011) and complement components (Tro-
edson et al., 2013), suggesting that these encoded proteins 
have particular roles more closely aligned to the maintenance 
of self-tolerance.
The acceptance of the type I interferonopathies as au-
toinflammatory disorders implies that autoinflammation 
can be considered as both interferon and noninterferon re-
lated. From a clinical perspective, it is clear that certain type 
I interferonopathies can present as “classical” autoinflam-
matory phenotypes, demonstrating recurrent fevers and/or 
organ-specific involvement with elevated markers of systemic 
inflammation in the absence of autoimmunity and under-
lying infection. At the same time, most patients conforming 
to this clinical description that we have tested show no ev-
idence of enhanced type I interferon signaling (unpublished 
data), lending support to the specificity of type I interferon– 
induced gene transcript measurement as a screening tool.  This 
distinction is likely also reflected in the observation that non-
interferon-related autoinflammation is not normally associ-
ated with a risk of lupus.
Cellular pathology and therapeutic approaches
The cellular pathology of the type I interferonopathies 
is associated with a diversity of mechanisms currently 
encompassing nucleic acid signaling in the broadest sense, 
proteasomal dysfunction and the unfolded protein response. 
Mouse work has been particularly instructive in defining 
the signaling pathways involved in several putative type 
I interferonopathies, so that we can now think of 11 of 
these genotypes as being transduced via cytosolic DNA 
(3), RNA (4) or RNA :DNA (4) hybrid sensing. Most 
type I interferonopathy genotypes relate to loss of protein 
function, whereas mutations in MDA5, RIG-I, and STI NG 
are associated with a gain-of-function resulting in either 
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constitutive activation of the relevant molecule and/or 
enhanced sensitivity for endogenous ligands.
We make the point here that different treatment strategies 
are implied according to pathological mechanism relevant 
to the type I interferonopathy being considered (Fig.  3). 
Thus, based on the hypothesis that type I interferon might, 
in certain AGS-related genotypes, be induced by cytosolic 
recognition of DNA derived from endogenous retroelements 
(Stetson et al., 2008; Beck-Engeser et al., 2011), we are 
currently running the first ever clinical trial in AGS, using 
reverse transcription inhibitors (https ://clinicaltrials .gov /ct2 
/show /NCT02363452). From a practical perspective, even if 
the precise nature of the interferon-inducing signal remains 
unclear in all cases, success in defining the signaling pathways 
involved in certain genotypes is already informing potential 
therapeutic strategies. Thus, as indicated in mice, inhibition 
of cGAS or STI NG would be predicted as relevant for 
TREX1- and RNA SEH2-related disease (Gall et al., 2012; 
Gao et al., 2015; Gray et al., 2015; Mackenzie et al., 2016; 
Pokatayev et al., 2016), but not for disease consequent upon 
mutations in ADAR1 (Liddicoat et al., 2015; Pestal et al., 
2015) or IFIH1 (Funabiki et al., 2014). We note recent work 
suggesting that antimalarial drugs such as hydroxychloroquine 
could be beneficial in this context, by antagonizing dsDNA 
stimulation of cGAS (An et al., 2015). In contrast, TBK1 
inhibition might be relevant to mutant genotypes induced 
by either DNA or RNA (Hasan et al., 2015). Notably, 
crossing of the Trex1-null mouse with mice heterozygous 
for any of cGAS, Tmem173, or Irf3 significantly ameliorates 
the otherwise lethal phenotype. Similarly, crossing the ENU 
gain-of-function Mda5 mutant with a Mavs heterozygote 
was associated with a marked reduction in the severity of the 
associated nephritis. These data are important in suggesting 
a degree of “suppleness” in the response to pathological 
signaling. That is, they indicate that future therapies blocking 
these molecules might demonstrate clinical efficacy at doses 
Figure 3. Outline of treatment strategies in 
the type I interferonopathies. Dependent on the 
underlying pathological mechanism, therapeutic 
approaches in the type I interferonopathies might 
include blocking the generation (e.g., using reverse 
transcription inhibitors: https ://clinicaltrials .gov /ct2 
/show /NCT02363452), sensing (e.g., cGAS inhibition 
by hydroxychloroquine [An et al., 2015]), or signaling 
(e.g., TBK1 inhibition [Hasan et al., 2015]) of putative 
self–nucleic acids engaging the type I interferon 
innate immune machinery and blocking of interferon 
itself (e.g., with anti–type I interferon antibodies), 
the IFN AR receptor, or the signaling cascades distal 
to interferon ligand binding (e.g., by JAK1 inhibition 
[Frémond et al., 2016]).
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that may not entail iatrogenic immunodeficiency consequent 
upon loss of signaling to viral nucleic acids. Perhaps relevant 
to this point also, our experience with JAK1/2 inhibition, 
see below, has so far been notable by the absence of an 
increased risk of infection.
As postulated here, all type I interferonopathy pathol-
ogy converges on up-regulated type I interferon signaling. 
Thus, any compounds that neutralize type I interferons, 
block the type I interferon receptor, or inhibit signaling 
downstream of the receptor might be of utility. Currently, 
no drugs are specifically licensed for any member of the 
type I interferonopathy grouping. We have recently de-
scribed the effect of JAK1/2 inhibition using ruxolitinib 
in the context of mutations in TMEM173, where we 
observed highly promising efficacy in all aspects of the 
clinical phenotype (systemic inflammation, destructive 
skin lesions, and pulmonary disease; Frémond et al., 2016). 
The same may also be true of proteasome-associated 
autoinflammatory syndromes (Jabbari et al., 2015). Anti- 
interferon therapy is being actively pursued in the treatment 
of SLE (Wang et al., 2013; Oon et al., 2016), with antibodies 
against the type I interferon receptor showing particular 
promise. We have not been able to test these molecules in 
any monogenic interferonopathy. Interestingly, inactivated 
interferon α 2b coupled to a carrier protein can induce the 
production of a polyclonal antibody response against all 
13 subtypes of interferon α, and a reduction of the associ-
ated interferon signature in high responders to vaccination 
(Ducreux et al., 2016). These data link nicely with those 
showing that patients with mutations in AIRE produce 
endogenous antibodies against all interferon α subtypes, 
but not interferon β, γ, or λ (Meyer et al., 2016). Despite 
the remarkably high affinity of these antibodies, consid-
erably greater than those used in commercial trials, these 
patients do not suffer an increased burden of viral infec-
tion, perhaps because they maintain antiviral protection 
through interferon β. If it can be shown that any type I 
interferonopathy relates predominately/exclusively to in-
terferon α, the therapeutic use of such antibodies might 
prove highly effective.
Finally, we highlight uncertainty regarding the cellu-
lar source of type I interferon production in distinct type 
I interferonopathies. Early data from the Trex1-null mouse 
indicated the importance of tissue-resident cells in disease 
pathology (Stetson et al., 2008), whereas more recent papers 
have emphasized a role for hematopoietic cells in driving 
disease (Ahn et al., 2014; Peschke et al., 2016). The latter 
results are important in pointing to a lack of current knowl-
edge relating to the efficacy of bone marrow transplant in 
any of the type I interferonopathies. Allied to this issue is 
the question of which cell types drive the brain involve-
ment characteristic of the majority of type I interferono- 
pathies so far identified (Cuadrado et al., 2015b; Goldmann 
et al., 2015) and of blood–brain barrier penetration in 
regards to drug therapy.
Conclusion
There has been a rapid adoption of the type I interferonopa-
thy paradigm, with the definition of 10 associated genotypes 
since the introduction of the term into the medical lexicon in 
2011. The study of the monogenic type I interferonopathies 
provides an unprecedented opportunity to define the role 
of type I interferons in human health and disease—through 
the identification of patients showing discrete molecular per-
turbation of proteins essential to interferon homeostasis. The 
model outlined here predicts that such studies will be of real 
clinical value as therapies to reduce type I interferon levels 
and/or block interferon signaling become available.
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